Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
May 8, 2020
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Natalia, and I'll be serving as your conference operator for today. I'd like to welcome all of you to the Cronos Group's First Quarter 2020 Earnings Conference Call. Please note that this call is being recorded today. At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Go ahead, sir.
Shayne Laidlaw
executiveThanks, Natalia, and I appreciate everyone being with us today as we go through Cronos Group's first quarter 2020 financial and business results. With me on the call are Mike Gorenstein, our Chairman, President and CEO; Jerry Barbato, our CFO; and Xiuming Shum, our EVP of Legal and Regulatory Affairs. This morning Cronos Group put out a news release announcing our financial results, and those are filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be available on our website under Investor Relations. Before handing things over to Mike, I want to remind everyone that during this conference call our discussion will contain forward-looking statements based on assumptions that carry risks and uncertainties, and those could make actual results differ materially from what the forward-looking statements project, including because of the factors laid out in the cautionary statement and risk factors contained in the company's earnings release and regulatory filings, contained in the company's most recent annual report on Form 10-K/A and quarterly report on Form 10-Q, and any forward-looking statements made during this call are qualified in their entirety by those documents. Also, during this call, certain financial measures may be discussed that are not recognized under U.S.
Shayne Laidlaw
executiveBroadly accepted accounting rules that the Securities and Exchange Commission calls non-GAAP measures. In our view, these non-GAAP measures help management with planning, forecasting, and assessing business and financial performance, including how resources get allocated. You'll find reconciliations of these non-GAAP measures to the nearest reported GAAP measures in our earnings press release furnished to the SEC, which can be accessed in the press room area of our website, thecronosgroup.com. These non-GAAP measures might not line up with measures other issuers use. I'd also like to mention that we're holding today's call from our separate remote locations. Because of that, there could be short delays, cross talk, or small technical problems during this call. We appreciate your patience and understanding ahead of time. We'll now deliver prepared remarks, and after that we'll move on to a question-and-answer session. With that, I'll hand things over to Cronos Group's CEO, Mike Gorenstein.
Mike Gorenstein
executiveThanks, Shayne, and good morning to all of you. With the COVID-19 pandemic still hitting markets across the globe and affecting people everywhere, we hope each of you is staying safe and well through this period. We want to open this call by talking about the impact COVID-19 is having on us and how our company is adjusting during this time. Safeguarding the health and safety of our employees and our consumers remains our number one priority, and so does making sure our supply chain is secure. As we said on our last call, we have put together a global cross-functional internal task force, and I lead it. We've been watching the situation every day so we can make changes as things develop. The company has rolled out business continuity plans to support its employees while we keep developing and producing reliable, high-quality products that meet and exceed what consumers need. As of today, our manufacturing facilities are still open, since governments in the regions where we operate have classified our business as essential. We are keeping our work-from-home policies in place for certain employees until further notice, and we have a strict no-travel policy, including between our sites, which are deemed essential. At our manufacturing facilities, we have strengthened hygiene and sanitation practices, adjusted schedules and kept social-distancing protocols in place.
Mike Gorenstein
executiveSince conditions differ from one region and country to another, we're working hard to keep complying with all relevant guidance issued by local, federal and international health and governmental authorities, and we stand ready to make further operational changes when needed. From our Peace Natural Campus, we've donated surplus N95 masks, goggles, face shield head mounts and face shield replacements to hospitals in the Collingwood and Barrie area. On top of that, the Lord Jones team has handed out skincare products to nurses and doctors at hospitals in New York, Miami, New Orleans and Houston. As a company, we count ourselves lucky to chip in, and we're honored to give back to our communities and to frontline health care workers as they care for COVID-19 patients. We'll keep watching the fast-moving COVID-19 situation very closely, along with how the reopening of different regions will affect the business, our consumers, employees and our supply chain. As you know, my focus and the company's focus are on creating long-term shareholder value by developing disruptive intellectual property and building iconic brands. I encourage long-term thinking, and especially in today's environment, we need to be planning for the future. Our value will come from technology breakthroughs and branded sales that help build and strengthen our relationship with our consumers.
Mike Gorenstein
executiveIn our view, the optimal path to generating value for the supply chain involves partnering with contract farmers and suppliers to meet our capacity requirements across global markets. In Q1 2020, NatuEra — Cronos Group's contract manufacturing joint venture in Latin America — hit major operational milestones. As a reminder, NatuEra operates as a 50-50 joint venture shared by Cronos Group and AGI, a business possessing multigenerational know-how in running industrial-scale agricultural operations for export out of Colombia. NatuEra finished building its state-of-the-art extraction facility, which was designed to GMP standards. NatuEra additionally secured preferential access to 4 cultivars registered with the Colombian Agricultural Institute. One of those hemp strains gets planted in mid-February and is harvested at the end of April. With its extraction and processing facility now also coming online, NatuEra's R&D department has created its first commercially available hemp-derived CBD distillate, which received a non-controlled substance ruling from Columbia's Narcotics Control Board, making the export process streamlined and efficient. NatuEra successfully wrapped up its initial test export to the United States in early March. The JV is concentrating on reaching new markets and expanding its product line, including developing further bulk offerings of hemp-derived CBD distillate along with water-soluble hemp-derived CBD solutions. Even though this was a small test shipment, we're extremely pleased with this joint venture and believe that our strategy of building a world-class, low-cost, scalable supply chain alongside partners such as NatuEra puts Cronos Group in position to develop new business and trade channels in geographies such as Latin America and other markets around the world.
Mike Gorenstein
executiveNow let's talk about what's new for us in Israel. After that quarter ended, during April 2020, Cronos Group finished shipping its inaugural bulk dried flower export to Cronos Israel, so that PEACE NATURALS branded cannabis products could be sold and distributed within the Israeli medical market. Cronos Israel is going to start establishing both its distribution network and its brand presence in this fast-expanding medical market. While we build that brand presence, we've been working alongside our JV partners at Kibbutz Gan Shmuel to get the Cronos Israel facility up and running. And it's encouraging to see that this operation should turn into a growth driver for our business during the back half of 2020 and beyond. We've secured the regulatory approvals required for producing, manufacturing and selling dried cannabis flower, and we're waiting on approvals covering pre-rolls and oil products, which should come through at points across 2020. I'd like to give you some detail on the Israel medical market and explain why we're eager to bring PEACE NATURALS's branded products to patients, with availability anticipated at some point in the second quarter of this year. Israel has implemented multiple measures aimed at streamlining and speeding up the process through which patients access medical cannabis, and we're thrilled to become part of this flourishing regulated market.
Mike Gorenstein
executiveIsrael's rate of cannabis consumption ranks near the top globally, and the number of medical patients there is projected to rise swiftly—an outstanding chance for our company to expand within that market. In 2016, a medical cannabis information booklet and guide was released by the Israeli Ministry of Health, containing a methodology designed for physicians to prescribe cannabis. Its purpose is to steer and support the tailoring of treatment involving medical cannabis. Numerous physicians across Israeli health care systems have undergone training and certification in this clinical methodology, allowing them to deliver treatment and grant patients licenses to possess and use medical cannabis. At present, the Israeli medical cannabis agency issues individual permits and prescriptions for medical cannabis to patients so they can be treated for various medical conditions. Also, in contrast to the Canadian medical cannabis program, patients obtain their prescriptions straight from pharmacies. The sophisticated legal framework already in place for medical cannabis in Israel, combined with a black market that is less established owing to Israel's strict border controls, creates a thrilling and potentially profitable opportunity for Cronos Group. In April, Cronos Israel signed a collaborative agreement with CannaSoul Analytics, a cannabis research firm focused on creating scientific intellectual property, medical products and technologies.
Mike Gorenstein
executiveAs part of the agreement we signed, CannaSoul plans to build a commercial lab for cannabis analytical testing right on-site at Cronos Israel. The company is headed by Professor Dedi Meiri, a well-established cannabis researcher at the Technion Israel Institute of Technology. Professor Meiri's plan is to run that laboratory and carry out in-house commercial analytical testing both for Cronos Israel and for clients from outside. When it is up and running, the lab's capabilities are expected to close the existing gap and meet the need in the Israeli market for accurate end-to-end cannabis analytical testing, covering domestic sales as well as export to certain international markets. We're very happy to be working with Dr. Meiri once more and to bring his expertise into the Israeli market. One more initiative that keeps us excited is the intellectual property work we're doing with Ginkgo Bioworks, along with our dedication to putting money into cutting-edge, breakthrough technologies in cannabinoid innovation. Each day brings us a step nearer to our vision of producing cultured cannabinoids at scale through fermentation. Ginkgo has already submitted patent applications, and those relate to fermenting cannabinoids so as to safeguard the intellectual property we've created so far via this partnership. As we mentioned before, we hold the exclusive global perpetual license to the intellectual property covered by those patent applications for the 8 target cannabinoids set out in our agreement with Ginkgo.
Mike Gorenstein
executiveDuring the first quarter of 2020, Cronos Fermentation obtained an R&D license from Health Canada, and we also received initial cannabinoid producing strains from Ginkgo Bioworks. After that quarter closed, Cronos Fermentation managed to successfully ferment CBGA, one of our target cannabinoids, using those cannabinoid strains at our Winnipeg R&D labs. Cronos Fermentation is going to keep working with these strains to optimize downstream processing and to scale up procedures ahead of obtaining the final strains and the commercial processing license — both are needed for commercialization. This pioneering work could transform our business and disrupt the industry in a number of ways. First, it will let us be more cost competitive as we roll out derivative products. As consumer demand moves away from flower toward derivative products, bringing down the cost of active ingredients is going to be critical if we are to compete effectively against our peers in the illicit market. Second, fermented cannabinoids are going to deliver products that are more consistent. Just like other consumer packaged goods companies, to build trusted cannabis brands that resonate with consumers, it is essential that we deliver the same experience every time a consumer interacts with our products. We expect the fermentation platform to give us the manufacturing precision needed to deliver consistent cannabinoid blends and products.
Mike Gorenstein
executiveAnd third, we intend to use rare cannabinoids so that we can offer consumers differentiated products and take a leading position as new product categories grow. Over the long term, differentiated products will support margin durability and market share, and cannabinoids will let us set our products apart within existing categories. On top of that, using rare cannabinoids as the primary ingredient in new product categories will let us broaden the addressable market. Having reached the milestone of successfully fermenting a cannabinoid at R&D scale at our facility, we remain confident in our ability to ferment cannabinoids commercially under the previously disclosed time line of September 2021. We expect that these cultured cannabinoids will one day not only form an integral part of our supply chain but also help our brand innovation potential reach new heights. This quarter, we continue to launch new innovative products and to further establish our brand portfolio. Our goal is to deliver high-quality, consistent cannabinoid products to the market while expanding how consumers approach and shop within the category. Early this quarter, our luxury hemp-derived CBD brand, Lord Jones, launched the Lord Jones Acid Mantle Repair CBD Moisturizer in the U.S. market. This soothing facial moisturizer is formulated to help maintain the skin's acid mantle and rebalance the appearance of stressed skin.
Mike Gorenstein
executiveThe brand keeps delivering on what it promises shoppers—genuine, authentic products—while also rolling out fresh, innovative items in skincare. Near the close of Q1, Lord Jones experienced a move toward the direct-to-consumer online channel, plus online purchases via its partner sites, since the majority of brick-and-mortar luxury retailers shut down because of COVID-19 and the social distancing orders that followed. Being an online-first operation, Lord Jones already has the infrastructure in place to satisfy online demand for hemp-derived CBD products. Even with our readiness to adjust to this evolving landscape—both near term and long term—consumer behavior doesn't always move as readily. We think the beauty category may see lasting effects when it comes to product trials and purchasing, because shoppers in the skin care segment usually prefer to try products in retail before buying them. In the Canadian 2.0 market, our direct-to-consumer medicinal cannabis brand, PEACE NATURALS, introduced new vaporizer devices during the first quarter. Quality has always been a top priority for our PEACE NATURALS brand, and that dedication to quality remains true with our new vaporizer devices. These devices are designed to give consumers a premium extract with precise cannabinoid concentration levels and terpene profiles for a consistent experience.
Mike Gorenstein
executiveOur premium cannabis extracts use CO2 extraction methods, and every product offers a distinctive, aromatic blend built on all-natural flavors rich in terpenes. Before sale, our PEACE NATURALS batteries and cartridges undergo rigorous testing, and feedback on these products has been positive so far. Quality is central to everything we do, and we take pride in that uncompromising approach. As we keep gathering more consumer insights about the Canadian market, we look forward to creating innovative, differentiated products that address what our consumers need and go beyond what they expect. Now to distribution in Canada. During Q1, we kept supplying the adult-use market, collaborating with provinces and private retailers to satisfy demand throughout this period. Because COVID-19 has affected global markets along with various industries and supply chains, we have started to observe a contraction in demand, since cannabis stores across various provinces have either shut or are undergoing changes in how they are being forced to operate. In Canada, although certain cannabis retailers were deemed an essential business, further new measures have been put in place allowing Click & Collect as well as online delivery of cannabis products to consumers. Similarly, several provincial purchasers have adopted additional health and safety measures and cut staff at on-site operations, including limiting delivery time slots, which has created logistical challenges and led to a reduction in purchase order fulfillment.
Mike Gorenstein
executiveRetailers are seeing fewer disruptions, but that comes on top of quarantine rules and travel limits that may hinder consumers' ability to easily get our products outside the online channel. Those restrictions will keep shifting and evolving, which makes forecasting consumer demand and sales velocity uncertain. As we mentioned in the U.S., while online sales carried on, most beauty and luxury brick-and-mortar retailers have temporarily shut their stores and boutiques. Still, Lord Jones has adapted during this period and has made, and will keep making, changes to meet online sales demand in this environment. Through these challenges, we keep adjusting and monitoring our distribution networks to bring quality products to market in this unprecedented time. We understand this disruption is affecting everyone, but we are committed to giving our consumers the same consistency and stability with our products that they have come to expect from our brands and from us. With that, I'll hand it over to Jerry to discuss this quarter's financial results and our remediation efforts.
Jerry Barbato
executiveThanks, Mike, and good morning to all of you. Moving on to the financial results. For the first quarter of 2020, consolidated net revenue came in at $8.4 million, which represents a 181% rise compared with the same period a year earlier. The year-over-year revenue increase was mainly attributable to greater distribution of cannabis products within Canada, along with the consolidation of financial results from Redwood, our U.S. hemp-derived CBD business acquired in September of last year. Consolidated gross profit for the first quarter of 2020 stood at negative $6.5 million, which is a decline of $8 million relative to the first quarter of 2019. The drop from the prior year stemmed chiefly from unfavorable pricing dynamics seen in the Canadian market, which resulted in an $8 million inventory write-down on dried cannabis and cannabis extracts in the rest of world segment, and also from higher marginal production costs at the Peace Naturals Campus, as we keep working toward running at full capacity following the repurposing of that facility in the fourth quarter of 2019. Excluding the $8 million inventory write-down, gross profit for the first quarter of 2020 would have been $1.5 million, reflecting a gross margin of 18%. As we mentioned in our fourth quarter 2019 earnings, we expect inventory write-downs to persist in the near term because of pricing pressures in the marketplace.
Jerry Barbato
executiveFor the first quarter of 2020, we reported an operating loss of negative $45.1 million, which represents a drop of $34.9 million compared with the first quarter of 2019. Several factors combined to produce that loss: general and administrative expenses driven by a larger headcount; sales and marketing costs tied to building out new brands as well as existing ones; and R&D expenses, chiefly from costs connected to our Ginkgo partnership and from innovation spending at the Cronos Device Labs research and development center. On top of that, there were internal review costs of $4.4 million, included in G&A, that related to the restatement of our 2019 financial statements. Our consolidated adjusted operating loss for the first quarter of 2020, which leaves out the onetime internal review costs, came to negative $40.7 million. Now to our reporting segments. The Rest of World segment posted net revenue of $6.3 million in the first quarter of 2020, up 108% from the prior year period. That year-over-year revenue growth was driven mainly by expanded distribution of cannabis products within the Canadian market, including the launch of cannabis vaporizers in both the adult-use and direct-to-consumer categories. Gross profit for the Rest of the World segment was negative $7.6 million, a decline of $9.1 million from the first quarter of 2019.
Jerry Barbato
executiveThe year-over-year decline came mainly from higher marginal production costs at the Peace Naturals Campus, along with an inventory write-down on dried cannabis and cannabis oil. Excluding that $8 million inventory write-down, first-quarter gross profit would have been $0.4 million, which works out to a 6% gross margin. I'd like to spend a moment on gross margin in the Rest of World segment. As we've discussed before, some facilities at the Canadian Peace Naturals Campus have been partly repurposed from cultivation to add space for R&D activities, manufacturing of derivative products, and more vault and warehousing capacity. Separately, we're also continuing to ramp up purchases from third-party cannabis producers so we can fully realize the benefits of our asset-light model. As we work to build an efficient global supply chain through 2020 and beyond, for our Rest of World segment, we expect gross margins to keep fluctuating and to face pressure. That's because certain manufacturing facilities being repurposed are currently underutilized, and work is still underway to streamline our third-party biomass supply chain. We expect these operational pressures to ease as our manufacturing and purchasing teams keep making progress in these areas.
Jerry Barbato
executiveNow, on our Canadian cannabis vaporizers, when we launched, we made a strategic choice to rely on contract manufacturers so we could get to market faster as Cannabis 2.0 legalization began. In addition, we think contract manufacturing gives us greater flexibility and responsiveness to marketplace trends, and it also fits with our asset-light model. We keep working with contract manufacturers to lower costs and make inventory movement more efficient, and we expect gross margins on our base to keep improving throughout 2020. The reported operating loss for the Rest of World segment in the first quarter of 2020 was negative $31.9 million, which is a $21.7 million decline from the first quarter of 2019. That loss was mainly driven by higher general and administrative expenses due to increased headcount, greater sales and marketing costs tied to building and developing existing brands, and higher R&D expenses in pursuit of our strategy. Our teams in Canada work diligently each day to properly configure and enhance our cannabinoid supply chain. We are creating an industry while at the same time executing a strategy that differs from our industry peers. We continue to believe in our strategy and its merits for long-term value creation. Turning to the U.S.
Jerry Barbato
executiveFor the segment, net revenue as reported for Q1 2020 came in at $2.2 million. The U.S. segment's gross profit was $1.1 million, a gross margin of 50%. The U.S. segment posted an operating loss of negative $6.5 million on a reported basis in the first quarter of 2020. That loss largely stemmed from higher sales and marketing spending tied to launching several new U.S. hemp-derived CBD products under the Lord Jones brand, along with added headcount to support growth initiatives. On an overall basis, Cronos Group saw net income fall versus the prior year, mainly because of the change in fair value of the financial derivative liability linked to Altria's investment, which the 10-Q describes in greater detail. During the first quarter, the company booked a noncash gain of $113.4 million tied to the change in fair value of those financial derivative liabilities. Cronos still expects that significant earnings volatility may be reported, driven mainly by quarterly fair value adjustments related to movements in Cronos Group's stock price. Moving to the balance sheet. The company finished the quarter with roughly $1.3 billion in cash and short-term investments, a decline of $171 million from the fourth quarter of 2019.
Jerry Barbato
executiveMost of that decrease came from exchange-rate volatility. Since the start of the year, the U.S. dollar has climbed considerably versus the Canadian dollar — from $1.30 on December 31 to $1.41 on March 31, 2020. Over the long term, this doesn't matter much for our business, and short-term currency swings should be expected, and generally they will continue down the road. Capital expenditures came to $7.5 million for the quarter. That outlay covers investments at our Peace Naturals Campus, Cronos Fermentation, our Israeli facility, and device technology innovation at Cronos Device Labs. Our focus stays on putting capital to work in a disciplined way and solely in manners consistent with our strategic priorities. Finally, I'd like to give you an update on the remediation work tied to the material weaknesses we disclosed last quarter. As a company, we are dedicated to establishing best practices for financial reporting. Our management, with the Audit Committee providing oversight, has launched a plan that we are diligently phasing in across 2020. I'll now walk you through further specifics of the remediation plan for each of the 3 material weaknesses we disclosed last quarter.
Jerry Barbato
executiveTo start, we're significantly upgrading the quarterly review process for our risk assessment model and risk controlled matrices, and we're also setting up a risk committee that will examine the risk assessment each quarter. Next, we're strengthening our delegation of authority policies so that fewer groups are able to authorize sales or purchases of inventory. In addition, we're putting in place a review process and an internal database to identify entities that are both vendors and customers of the company. Finally, we are currently creating and implementing a non-routine transactions policy that will clearly define non-routine transactions, with prior accounting memo completion, and will require CEO and or CFO approval. Business operators will need to provide formal business cases for all non-routine business-to-business, unbranded sales and purchases. Those business cases will be reviewed quarterly to ensure alignment with the objectives of the company. We will also be expanding the sub certification process to additional members of management to ensure that non-routine transactions are correctly identified and accounted for. As we implement these controls, they will be rigorously tested internally and by our independent auditor to ensure they are working correctly. We are confident in our remediation plan that we are implementing and believe we will be a stronger company as a result of this undertaking.
Jerry Barbato
executiveTo wrap up, we anticipate ongoing investment in our strategic initiatives, and we stay optimistic regarding our near-term plans for attaining long-term leadership within the cannabis space. With that said, I'll hand things over to Mike for closing remarks ahead of Q&A.
Mike Gorenstein
executiveThank you, Jerry. Cronos entered 2020 with real energy and a firm resolve to keep delivering on the strategic initiatives that drive sustainable growth and long-term value. Even with the difficulties and unpredictability created by the COVID-19 pandemic, as a business we stay focused, nimble, and less in need of leaving our homes. As we adjust to a distribution model that puts online first in both the U.S. and Canada, our brand portfolio keeps bringing innovative products to consumers. Through inventive digital marketing, we keep connecting with our stakeholders and consumers. We believe our company's mission—improving lives through cannabinoid innovation—resonates with particular strength, and we consider ourselves very lucky to be able to offer consumers our products during these times. We stay well positioned and dedicated to producing sustainable long-term value for shareholders, and we are confident that 2020 will be a successful building year for Cronos. With that, let's now open the line for questions.
Operator
operator<<operator_script>> Our first question comes from Andrew Carter at Stifel.
W. Andrew Carter
analystLet me return to Lord Jones and the U.S. platform side of things. It came in lower on a sequential basis versus the prior quarter, and basically level with where it stood in the third quarter. There are plenty of moving pieces here. Shipments to certain stores that are shutting are clearly lower. But what can you offer — and there are also some new product launches — in terms of growth coming from existing customers in your direct-to-consumer channel? Or anything that would give us some evidence the brand is connecting with people and expanding?
Jerry Barbato
executiveThanks, Andrew. It was somewhat disappointing to watch the U.S. business decline, but we have confidence in the plans the business has in place to get things back on track. Those plans include — but aren't limited to — raising consumer awareness of both new and existing products, like the Lord Jones Acid Mantle CBD moisturizing cream that Mike referenced in the prepared remarks, plus another brand launch that's coming in the second half of 2020. For us, the U.S. CBD market represents a major opportunity, and we look forward to sharing more about what's in the pipeline and with our consumers as time goes on. The other item I'd like to address is how COVID-19 has affected us. We have a large B2C business, but we also work with many retail partners — over 900 — and a lot of them are currently closed. While some of that volume has moved to certain online platforms, many of these are boutiques with no online platform at all. So there could be some pressure — certainly pressure in Q2 — and we'll see how things look in Q3 and Q4.
W. Andrew Carter
analystNow let's move on to discussing the other main channel for your company. From what I gather about your Canada forecast, you seem to be pointing toward some near-term strain on sales. So how are you viewing the opportunity in Canada and how you're positioning the business for this year? Should we be expecting a short-term drop-off, followed by a very swift rebound as soon as the restriction gets lifted? Or are you perhaps also factoring in some longer-lasting effects, clearly, like a delayed retail rollout and certain closures — how are you approaching the evolution of these channels and your positioning across the coming 6 months to 1 year?
Mike Gorenstein
executiveOkay, so over the long term, nothing we've observed has altered our outlook on how this market will unfold between the next 6 months and 1 year, and my sense is that conditions are going to be choppy. One element of what we've observed involves abrupt shifts and the shape distribution will take. It's also quite hard to generalize across all of Canada, simply because provinces differ in the approaches they've taken in responding to COVID. So I think we may see some shifts in product mix and pack sizes. And if we consider the occasions consumers will be buying for, bearing in mind more time spent at home, then I think convenience formats become less of a priority, so perhaps a greater shift toward flower. And I think we're actually still going to see some store growth. We've seen some stores in Ontario continue, but I think rather than expecting declines, perhaps just -- whereas we were conservative in forecasting what the growth would be this year, it's likely that just the expected growth may not be there. But I think, given the asset-light model and the flexibility we have, we're confident that the strategy remains right and that we'll be able to be ready to hit the ground running as soon as things start opening back up.
Operator
operatorThe next person to ask something will be Michael Lavery from Piper Sandler.
Michael Lavery
analystCould you expand a bit more on CBG or CBGA? You said you'd like to be positioned with differentiated products—could you give us perhaps a teaser of what that might look like and which elements would set it apart? And maybe specifically, in part, how do you educate the consumer so they understand how it differs from other cannabinoids?
Mike Gorenstein
executiveAbsolutely, and thanks for asking that. Our view is that consumer buying patterns for CBG will end up resembling those for CBD. As with CBD, additional research is definitely still required prior to making any particular claims. What I believe we'll discover is that many of the motivations behind CBD purchases may translate into a superior experience for a specific need with CBG. So in that sense, I think there will be a component of more effectively meeting what CBD consumers are looking for today. That said, I also believe there remains a chance to grow the addressable market somewhat. You could think of the formats as being broadly alike — anything that isn't an intoxicating cannabinoid falls into that bucket, while THC sits on the opposite side. In fact, we've observed CBG available in modest volumes, with robust demand in the U.S. My view is that additional supply is necessary before pricing dynamics can be forecast, yet because of the scarcity we've seen it commanding a higher price point. Still, we see 2 genuine routes for bringing it to market. The first involves positioning CBG as the lead cannabinoid, making it a distinct category and a point of differentiation.
Mike Gorenstein
executiveThe other piece involves bringing CBG into the picture and presenting it as one component of a blend alongside additional cannabinoids.
Michael Lavery
analystAlright, that's useful. Just one quick follow-up question. Could you give us a feel for some of the—you said you expect inventory write-downs still ahead. Can you offer any indication of how large that risk might be? Would it be comparable to what we saw this quarter, or bigger, or smaller?
Jerry Barbato
executiveRight, we don't provide any forward-looking guidance. So much of this hinges on how fair value plays out in the Canadian market.
Operator
operatorThe next person to ask something is Vivien Azer from Cowen.
Vivien Azer
analystTo follow up regarding the Canadian landscape: many of your rivals have rolled out value-priced, discount, or deep-discount off rates. Given that competitive activity, what impact are you observing when it comes to the overall pricing landscape?
Mike Gorenstein
executiveAbsolutely. This is definitely something we're observing, and in some categories we are seeing price elasticity. In flower, we do expect price compression, and we always have. From a platform standpoint, we believe much of the work we're doing—and have been doing—around innovation with fermentation will leave us well positioned to stay price competitive and to lead while generating value from those segments. That said, I think two factors are really behind the changes. One is clearly value. When you can spread the product across larger pack sizes, your cost is lower. But there's also the fact that consumers are at home right now, and I think you'd see a move toward larger pack sizes regardless of—or sorry, independent of the drastic shift in prices. So those two factors are certainly gaining traction, in our view. And for flower, we don't expect any drastic change to that trend at any point soon. If you look at other markets—the legalized markets in the U.S.—what you typically see is that pricing begins at a fairly high level.
Mike Gorenstein
executiveIn a situation where demand is strong but supply is scarce, you'll observe the price declining gradually. Then, once a certain threshold is reached, you'll notice pricing begin to climb again and shift toward an equilibrium, since operators will start leaving the market. A key reason we chose to team up with the Mucci group on Cronos GrowCo is, in my view, their capacity to succeed in other produce markets that show comparable patterns. That is roughly how we view the way the flower market is taking shape in Canada.
Vivien Azer
analystThat's quite useful, and I have one quick follow-up. You brought up the move toward bigger pack sizes as stay-at-home orders took effect — which, of course, is logical and matches what we're observing across other CPG categories. Still, when it comes to demand planning, Mike, do you assume consumption will stay at higher levels for as long as people remain at home? With the current backdrop in mind, how are you viewing the way consumer demand will evolve?
Mike Gorenstein
executiveSure. We lack sufficient data to support that claim. And while we can certainly envision it as a possibility, some factors are hard to forecast, like what portion of consumption and purchasing will originate from the legal market versus the illicit one. And I think product mix is another crucial element for us to consider. When it comes to demand planning, given how long it takes to alter pack sizes and modify offerings, and how long we believe that would persist, we do take it into account — we're kind of watching where things are headed, since we're in Canada, I'll put it as where the puck is going, not where it is. And I'm not sure a sustained move toward large pack flower size is where we perceive the value lying in the long term. We recognize there's some degree of that. But again, returning to convenience and usage, certain advantages from formats have us quite enthusiastic where convenience really counts, pre rolls, vape pens, edibles, I think that carries a lot of emphasis. So in our near-term demand planning, a mix shift is simply far more probable than a shift in overall product quality.
Operator
operatorWe'll now take a question from John Zamparo at CIBC.
John Zamparo
analystI'd like to come back to that other question regarding CBGA. To me, that's a pretty interesting development. So could you expand a bit more on your overall biosynthesis approach? And suppose you hit those milestones that you mentioned, Mike, or perhaps get there sooner than you anticipate — are there further steps required before you can monetize and commercialize that research? Do regulatory approvals come into play? Or is it possible to launch products the moment you have them? And if additional work with Technion or CannaSoul is needed — I suppose at this point? Anything at all you can share that would help us frame that strategy would be useful.
Mike Gorenstein
executiveAbsolutely. Thank you, John. So there are a few different angles to consider here. First off, whether you're looking at THC, CBD, or even CBG, we've managed to observe a certain amount of limited data regarding how these products get used. When it comes to items we currently have on the market, or even items we plan to launch irrespective of fermentation — anything that isn't flower — we can simply swap in fermented cannabinoids, since they are entirely fungible. The molecule is precisely the same as cannabinoids derived through extraction from cultivation. So right from the start, monetization doesn't require anything beyond the commercial processing license at our Canadian facility; that would work just the same as having a third-party — or rather, a second extraction site. The process we must follow is in fact explicitly laid out in C-45, which states that cannabinoids for processing may originate from biosynthesis. Thus we regard them as fungible and capable of entering the supply chain immediately. I think additional research and effort we're currently undertaking concerns products in which rare cannabinoids serve as the lead product.
Mike Gorenstein
executiveIf we decided to bring out a THCV vape pen — with THCV as the main cannabinoid and a formulation that's entirely new to the world — that's research we're continuing to work on right now. As for the skincare research at Technion, there's definitely still work that needs doing there. We're excited about it, sure, but we still have a ways to go. Now, the other route for getting value out of rare cannabinoids is what I mean when I say simply swapping them into our supply chain. Take any popular cannabis product on the market today — actually, I should say most cannabis products today — and look at how the ingredients break down. What you'll find is that THC and CBD are the 2 primary cannabinoids, but as you move further down the lab printout, CBG, CBC, CBDV, THC, all the Ginkgo targets, are in fact in there. And when you consider the entourage effect and what consumers are after for a differentiated experience — when someone says they want a White Widow versus Northern Lights, it's really those cannabinoids and the turbines driving that unique effect and that unique blend consumers want. And that gives us the ability, within our supply chain, to make sure we provide that unique blend every time and just deliver the same experience.
Mike Gorenstein
executiveFrom that standpoint, no adjustments are necessary on our end. For formulations that are new to the world, though, we still have research ahead of us. My expectation and hope is that this research will continue for years, letting us keep building our innovation pipeline as they test, refine, and perfect offerings.
John Zamparo
analystOkay, that helps a lot. My follow-up question is about brand building. I just want to understand how you’re thinking about building brands given the current COVID situation. In the past, you’ve mentioned launching more brands through the Redwood family or Redwood asset, but your distribution partners are quite limited at the moment. So does that push the brand launch to 2021? Or was that basically the plan regardless?
Mike Gorenstein
executiveI think there are definitely factors that could slow down how we'd otherwise launch, or maybe delay an optimal launch. But we have to accept the reality that this can drag on for an extended period. So we do have contingency plans in place. When we look at the brands in our portfolio and consider timing, we feel that for certain elements of a brand we'd launch, we believe we can build awareness without a retail presence, which wouldn't be optimal. So I think becoming digitally native, leveraging the brand through DTC, and being able to use social media — there are many avenues through which we can still launch, and we plan to launch DTC, with core stone monitoring the situation, if that's the only option available to us.
Operator
operatorWe'll now take a question from Rahul Sarugaser at Raymond James.
Rahul Sarugaser
analystMike and Jerry, congratulations on completing the tech transfer from Ginkgo to the Winnipeg facility. That's obviously a significant milestone, and it looks like a growing piece of your strategy. So we see that the first cannabinoid is CBGA, and I wanted to dig a bit deeper into how many more cannabinoids you expect will be tech transferred over to the Winnipeg facility in the next year, and as you get closer to that September 2021 timeline?
Mike Gorenstein
executiveSure. Yeah, I think we — without diving into the details of exactly how many have actually been tech transferred so far, I'd just say that we do anticipate having every cannabinoid transferred across the various strains by December 2021 of next year. For us, I think the general fermentation process is really the most important piece of that milestone. And when you consider just how alike our targets are when it comes to the molecule, it's about being able to begin the scale-up and downstream processing work, being able to figure out where the kinks are and where the potential bottlenecks sit, whether in fermenting or harvesting or separation, and just being able to achieve the conversion from the strain to the broth to the purified cannabinoid — so that process matters, and the important thing is having a strain in a cannabinoid, but the molecules are so similar that we don't see any difference in what those processes are really going to be. But timeline-wise, we still expect that we'll be able to bring things to market in September 2021.
Rahul Sarugaser
analystThanks. One quick follow-up, if I may. For those first-generation products, is your expectation that they'll be entirely synthetic? Or do you see a combination formulation being used — some synthetic plus some botanically derived isolates?
Mike Gorenstein
executiveYeah, and I think that's a hard one to answer — it could be a mix of things. I do believe that for many products, keeping some of the fats, waxes, and terpenes in there offers certain advantages. But in the end, consumers will determine what the product mix looks like. So we see value in being able to strike the right balance and keep our offerings consistent. We haven't observed that isolate products are necessarily something consumers are especially interested in today. So it would be a combination of fermented cannabinoids, or a mix of fermented and botanical — though based on consumer research, I'd say it's more likely that in the early stages, as we ramp up and think about run-on run-off times, switching between different cannabinoid runs, and figuring out efficiencies, it would begin as more of a blend.
Operator
operatorOwen Bennett from Jefferies has the next question.
Owen Bennett
analystI trust everyone is doing well. My first question concerns the write-downs and where you anticipate further additional costs. I was wondering what your view is on that and why, given the arguably greater scrutiny on your reporting, you don't simply take one big write-down at the outset now, as a lot of your peers appear to be doing?
Jerry Barbato
executiveYes. Thanks, Owen, and good morning. Well, as you can probably imagine, this is quite a dynamic period for the company, since we're retooling our Canadian business for 2.0 products and expanding our strategy of purchasing third-party biomass. And I'd direct you back to the factors we set out in our prepared remarks, like the near-term underutilization of the Peace Naturals Campus and the stabilization of our third-party biomass supply chain. Essentially, you've seen this happen with others in the industry — your gross margins can take a hit when facilities aren't being used to their full capacity. It's simply a product of the fact that there isn't enough revenue to cover the facility's fixed costs, and we see that improving as the year goes on.
Mike Gorenstein
executiveThere's one more thing I want to mention. Some fixed price contracts are still being resolved, and we simply expect that price compression will keep showing up on the supply side. I'd also note that, when you compare us with competitors, it's worth keeping in mind that as far as I know, just one other competitor currently reports under GAAP. So the way we handle accounting is probably not the same as what most of the competitors who remain on IFRS do.
Owen Bennett
analystAll right. My follow-up, then, is this: you've discussed the continuing move toward value and the price compression, and with another write-down looking likely, it really seems your flower is moving slowly at retail right now, and it's still among the priciest offerings on the market. So I was just wondering — what's the plan there? Do you intend to hold prices at current levels? Or will you bring them down given how little is selling through? Because if it's the first option, it rather looks as though you're essentially giving up on the flower business while hoping — obviously, you mention these value-added products — that once they begin to arrive and revenue starts flowing from them.
Mike Gorenstein
executiveYeah. No, for competitive reasons, I think we just won't address what our approach to pricing is going to look like going forward. But of course, that's something we continually assess, and we want to be sure we remain competitive in the marketplace and are meeting consumer needs.
Operator
operatorMatt Bottomley from Canaccord Genuity has the next question on the line.
Matt Bottomley
analystI just wanted to dig a bit further into domestic cannabis sales, or penetration, this quarter versus the prior one. So I know you included some details in the prepared remarks, but you had a decent percentage bump up to $6.3 million. Still, in absolute dollars, I would have expected potentially a larger bump given the 2.0 product introduction. So if you could maybe just give us some color on the quarter-over-quarter growth and how that lines up with what happened with the vape pens? And then also, how much contribution might have shifted to incremental international sales? It's still unclear to me how much of exports in the period might have been in that number?
Mike Gorenstein
executiveOkay. So — and I think one thing worth examining is how much growth we observed in branded sales and penetration. I think we've definitely witnessed a bit of a mix shift, since purchases either excluded 2.0 or contained only a small quantity of 2.0, and now consumers can choose between both. But I think things are — what's going well is how positively the vape pens have been received, and we expect that to ramp up over the course of the year. On the international side, we actually haven't observed any shift in export demand. It's really about scheduling and logistics. But looking ahead at growth, we're adding a new region. And I think when you consider all the various medical markets that have launched, Israel, despite being a relatively new commercialized market, is somewhere we've had a great deal of infrastructure. And I think the regulators have done an excellent job ensuring it's successful, both for medical patients and for businesses. So we do expect growth to come from Israel, beginning, I'd say, with the flower we've exported.
Mike Gorenstein
executiveEven so, our facility is operational and we've managed to bring in a harvest. So with the shortage over there and demand that we've observed to be fairly substantial, without much of a black market relative to what we see in North America, we anticipate growth will come in that market. That said, I'd note it isn't coming solely as an export market. Much of it is going to come from cultivation domestically, though depending on where demand settles, it could remain a combination of exports and domestic cultivation.
Matt Bottomley
analystUnderstood. As a quick follow-up, any color you can offer on pricing — either in dollar terms or simply as a ratio relative to what you see in the Canadian medical market? I know historically your pricing in Germany was quite favorable. So I'm just curious how that plays out in Israel.
Mike Gorenstein
executiveYes. I don't think it will reach the level seen in Germany. Germany, in my view, is quite unique. What I'd say is that we anticipate — and I don't mean to come across like an economics lecturer — that there isn't the same distinctive obstacle you find in Germany, given how the pharmacy system operates and how it practically locks prices in place. So in markets of that kind, we've observed there can be a scarcity of the high-price segment, but our real emphasis is on cultivating relationships with consumers and patients and securing early market share. This is a market we intend to push into seriously. So I'd say pricing will be nearer to what we observe in Canada, at least in terms of how we approach setting prices. That said, we do anticipate production costs being lower in Israel, and I believe we've pointed that out on earlier calls, simply because of the climate. So we still see a solid margin opportunity. Over time, though, we'd anticipate trends in product mix resembling those we've seen in Canada, since from a regulatory standpoint it's comparable, with the main distinction being that it goes through pharmacies instead of directly to the patient.
Mike Gorenstein
executiveIt might therefore land somewhere in the range between Canada's adult-use and medical markets. Still, I believe Germany belongs in a category of its own, because of its more traditional pharma model.
Operator
operatorThe last question comes from Graeme Kreindler at Eight Capital.
Graeme Kreindler
analystI wanted to ask a follow-up question about the U.S. CBD pipeline launches that are expected in the second half of 2020. Lord Jones has traditionally been positioned as more of a premium brand. Given the potential for economic headwinds stemming from COVID-19, I was wondering whether there are any plans to launch a more mainstream or value-type product.
Jerry Barbato
executiveAbsolutely. Appreciate that, Graeme. Without a doubt. Lord Jones, as everyone knows, sits in that super premium tier at a high price point. So when we consider the consumer segment, launching a far more mainstream brand is clearly a major opportunity for us, and that's certainly part of what we have planned.
Graeme Kreindler
analystOkay, and as a follow-up here, I was just wondering — with what's happened recently at Altria and the leadership changes there, could you give us a bit of color on how the relationship between the 2 companies stands? And any discussions that have taken place during the transitions, or as the business mix there keeps developing. That would be helpful.
Mike Gorenstein
executiveAbsolutely. From what I can see, the conversations haven’t shifted at all. As far as we’re concerned, the group over there is the same one that has been in place for as long as the relationship has existed. And I’d say Jerry likely has his own unique connections with the people there as well. That said, I think executive tenure there has remained quite steady. So in terms of our discussions, there really haven’t been many shifts. Much of what we’ve concentrated on over the last few months has involved receiving considerable support from many of the people there and their counterparts. I’m just running through COVID, running through possible effects, running through what best practice looks like in manufacturing, and making sure the right procedures are in place so we can prioritize employee safety and figure out how to handle things. So I’d call it a highly collaborative relationship, and I think we’ve been quite lucky to be able to draw on their expertise for how to navigate fairly uncertain times. But at a high level, there have been no changes and no discussions.
Jerry Barbato
executiveYeah, and I'd say the switch has gone really smoothly on our end. The teamwork across the group, I think, keeps going and is likely growing even more.
Operator
operatorThat wraps up our Q&A. Today's conference call has now reached its end. We appreciate everyone taking part. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.